CARMELINA confirms linagliptin’s renal, CV safety, but it’s still third-line for type 2 diabetesJuly 16, 2019Diabetes
BMI screening trigger for type 2 diabetes is unreliable for at-risk black, Hispanic adultsJuly 12, 2019Diabetes